covid-19 pipelines cell therapies, diagnostics, treatments and … › ... · 2 days ago ·...

COVID-19 Pipelines – Cell Therapies, Diagnostics, Treatments and Vaccines | BioInformant.com

____________________________________________


____________________________________________

1. REPORT OVERVIEW

1.1 Statement of the Report

1.2 Executive Summary

1.3 Introduction

2. CORONAVIRUS: STRUCTURE, INFECTION, REPLICATION, SYMPTOMS

2.1 Start of the Outbreak

2.1.1 Structure of COVID-19

2.1.2 Structure of COVID-19’s Spike Protein and Enzymes

2.1.3 The Details of COVID-19’s RNA-dependent RNA polymerase (RdRp)

2.1.4 Crystal Structure of COVID-19 Virus’s Protease Enzyme

2.1.5 Structure of COVID-19 virus’s Spike Protein

2.1.6 The Binding of a Patients Antibody with COVID-19 Virus’s Spike Protein

2.1.7 Potential Binding Sites of Human Protein Complex (CUL2ZYG11B)

2.1.8 The Binding of Coronavirus to Target Protein on Human Cell

2.1.9 The Cause of COVID-19 Virus’s Rapid Spread

2.2 The Symptoms of COVID-19

2.3 Progression of COVID-19

2.4 The Incubation Period for COVID-19

2.5 Duration of the Disease

2.6 Case Fatality Rate

2.6.1 CFR for COVID-19 by Age

2.6.2 CFR for COVID-19 by Pre-Existing Health Issues

2.6.3 Case Fatality Rate for Select Countries and the World

2.7 Modes of COVID-19 Transmission

2.8 Clinical Case Management

3. GLOBAL STATISTICS ON COVID-19

3.1 The Steady Increase in Global Number of Confirmed Cases

3.1.1 Steep Increase in COVID-19 Deaths

3.1.2 Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020

3.1.3 Number of COVID-19 Deaths by Geography as of May 21, 2020

3.1.4 China Returning to Normalcy

3.1.5 COVID-19 Deaths in China

3.2 Top Five Most Affected Countries

3.2.1 COVID-19 in the U.S.

3.2.1.1 COVID-19 Deaths in the U.S.

3.2.2 COVID-19 Confirmed Cases in U.K.

3.2.2.1 COVID-19 Deaths in U.K.


____________________________________________

3.2.3 COVID-19 Confirmed Cases in Italy

3.2.3.1 COVID-19 Deaths in Italy

3.2.4 COVID-19 Confirmed Cases in France

3.2.4.1 COVID-19 Deaths in France

3.2.5 COVID-19 Confirmed Cases in Spain

3.3 COVID-19 Deaths Compared with Deaths Due to Other Diseases

3.4 The Ebb and Flow of COVID-19 Cases

3.5 Africa Spared the Worst of the Pandemic

3.6 Number of Laboratory Tests Conducted by Select Countries

3.7 Top Four Countries with Number of COVID-Tests

4. FUNDING FOR COVID-19 RESEARCH

4.1 Contributions to WHO for COVID-19 Appeal

4.1.1 Contingency Fund for Emergencies

4.2 National Institutes of Health (NIH) Funding for COVID-19 Research

4.3 Funding for COVID-19 Research from U.S. Stimulus Bill

5. PUBLISHED SCIENTIFIC PAPERS ON COVID-19

5.1 Published Papers by Category

5.2 Notable Journal Articles

6. PATENTS OF SARS AND MERS WITH POSSIBLE RELEVANCE TO COVID-19

6.1 Types of SARS and MERS Patents

6.2 Key Proteins Described in the Patents and their Roles in Viral Infection

6.3 Patents and Potential Drug Candidates Related to Key Protein Targets

6.4 Patents of Existing Drugs with Potential Applications for COVID-19

6.5 Selected Patents Related to Small Molecule Drug Candidates

6.5.1 Compounds with Potential Effects on Key Proteins of COVID-19

6.5.2 Small Molecules Identified by Structure Similarity and Therapeutic Usage

6.6 Distributions of Biologics Patents Related to SARS and MERS

6.6.1 Patents of SARS Antibodies

6.7 Distribution of Patents of Vaccines Related to SARS/MERS

6.8 Distribution of RNAi Patents related to SARS/MERS

7. CLINICAL TRIALS LANDSCAPE FOR COVID-19

7.1 COVID-19 Clinical Trials by Country/Region

7.2 Clinical Trials by Study Type

7.2.1 Types of Interventions in the Ongoing COVID-19 Clinical Trials

7.2.1.1 Proposed Pharmacological Interventions in COVID-19 Clinical Trials


____________________________________________

7.2.1.2 ATMPs under Investigation in COVID-19 Trials

7.3 COVID-19 Clinical Trials by Stage of Development

7.3.4 COVID-19 Clinical Trials by Funding Type

7.3.4.1 Industry-Sponsored Clinical Trials against COVID-19

7.4 Upcoming Readouts from Ongoing COVID-19 Clinical Trials

8. COVID-19’S NEGATIVE/POSIVE IMPACTS ON HEALTHCARE INDUSTRY

8.1 Negative Impacts

8.1.1 Disruption of Big Clinical Trials by COVID-19 Pandemic

8.1.2 15-Fold Increase in Clinical Trial Suspensions

8.1.3 Specific Examples of Clinical Trials Threatened by COVID-19

8.1.4 Delayed Readouts due to COVID-19

8.1.5 Shortages of Patients for Phase III due to COVID-19

8.1.6 Most Hit Pivotal Trials

8.1.7 Threat to Trials of Near-Term Blockbusters

8.1.8 COVID-19’s Deleterious Effects on Elective Procedures

8.1.9 COVID-19 Infected Cardiovascular Companies

8.1.10 Delayed Acquisitions due to COVID-19

8.1.11 Stalling of Biotech Flotations by COVID-19

8.1.12 Financial Damages to the Pharmaceutical Industry due to COVID-19

8.2 Positive Impacts

8.2.1 Sizeable Opportunities for Some Collaborations

8.2.2 COVID-19 Market Movers

8.2.3 COVID-19 Events that Pushed the Share Prices up

8.2.3.1 Johnson & Johnson

8.2.3.2 Gilead Sciences

8.2.3.3 Roche

8.2.3.4 Sanofi

8.2.3.5 BioNTech

8.2.3.6 Moderna

8.2.3.7 Vir Biotechnology

8.2.3.8 Takeda

8.2.3.9 CytoDyn

8.2.4 COVID-19-Related Stock Risers


____________________________________________

9. MEDICINES IN DEVELOPMENT FOR COVID-19

9.1 The First Medicine to Reach the Market

9.1.1 Spectrum of Drugs

9.1.2 Difficulties in Making a Drug in Time

9.1.2.1 Bargain Search

9.1.2.2 Three Stages in Development

9.1.2.3 Massive Demand

9.1.3 Generic for Remdesivir

9.1.4 Concern about Access to COVID-19 Medicine

9.2 FDA’s CTAP to Accelerate COVID-19 Drug Development

9.2.1 CTAP’s Activities in a Snapshot

10. EMERGING VACCINE TREATMENTS FOR COVID-19

10.1 Protein Sub-Unit Vaccines in Development against COVID-19

10.2 RNA-Based Vaccines

10.3 Non-Replicating Viral Vector Vaccines

10.4 DNA Vaccines in Development for COVID-19

10.5 Inactivated Virus Vaccines in Development for COVID-19

10.6 Virus-like Particle Vaccines in Development for COVID-19

10.7 The Nearest Vaccine

10.8 Additional COVID-19 Vaccine Projects

10.9 CEPI’s Call for Vaccine Fund

10.10 Clinical Trial Costs for Developing a Viral Vaccine

10.11 The Usual Pattern of Revenue Generation by Viral Vaccines

10.11.1 Historical Sales of Vaccines for Previous Pandemics

10.11.2 Historic Sales of H1N1 Influenza Vaccines

10.12 Recent Vaccine Collaborations

10.13 Companies Capable of Producing Vaccines on a Global Scale

10.14 Big Pharma in COVID-19 Vaccines

11. ANTIBODY THERAPIES IN DEVELOPMENT FOR COVID-19

12. ANTIVIRAL DRUGS IN DEVELOPMENT FOR COVID-19

12.1 Estimated Cost of COVID-19 Antiviral Therapeutic Development

12.2 A Competitor for Gilead

12.3 Remdesivir: The First to Reach the Market

12.3.1 Hints of a Hope from Remdesivir Results

12.3.2 Interim Data for Remdesivir

12.3.3 Sales Forecast for Remdesivir


____________________________________________

12.4 Structure of Remdesivir

12.4.1 Mechanism of Action of Remdesivir

12.5 Additional COVID-19 Therapeutic Projects

13. REPURPOSED DRUG CANDIDATES AGAINST COVID-19

14. CELL-BASED THERAPIES IN DEVELOPMENT FOR COVID-19

14.1 Brief Descriptions of Stem Cell-Based Clinical Trials for COVID-19

14.1.1 NCT04313322 (Stem Cells Arabia)

14.1.2 NCT04366063 (Royan Institute)

14.1.3 NCT04252118 (Beijing 302 Hospital)

14.1.4 NCT04346368 (Guangzhou Institute of Respiratory Disease)

14.1.5 NCT04331613 (Chinese Academy of Sciences)

14.1.6 NCT04390139 (Banc de Sang i Teixits)

14.1.7 NCT04355728 (Camillo Ricordi)

14.1.8 NCT04299152 (Tianhe Stem Cell Biotechnologies, Inc)

14.1.9 NCT04269525 (ZhiYong Peng)

14.1.10 NCT04390152 (BioXcellerator)

14.1.12 NCT04362189 (Hope Biosciences)

14.1.13 NCT04371393 (Icahn School of Medicine/Mesoblast, Inc)

14.1.14 NCT04365101 (Celularity Incorporated)

14.1.15 NCT04367077 (Athersys, Inc)

14.2 MSCs: The Most SuiTable Cells to be used Against COVID-19

15. MEDICAL DEVICES IN DEVELOPMENT FOR COVID-19

15.1 The Scramble for Mechanical Ventilators

15.2 Ventilator Shortages

16. COMMERCIALLY AVAILABLE DIAGNOSTICS FOR COVID-19

16.1 PCR Tests (Viral RNA Tests)

16.2 Serology Tests (Antibody Tests)

16.3 Antigen Tests

16.3.1 Number of EUAs Granted to Viral RNA Tests and Antibody Tests

16.3.2 Specific Issues with Antibody Tests

16.3.3 Roche’s Antibody Test: Maximum Sensitivity and Specificity

16.4 The First COVID-19 Antigen Test

16.5 At-Home COVID-19 Sample Collection Kit

16.6 Top Ten COVID-19 Diagnostic Companies

16.7 The Deluge of Testing Options


____________________________________________

17. MARKET ANALYSIS

17.1 Global COVID-19 Vaccine Market

17.2 Global Market for Antiviral Drugs against COVID-19

17.3 Global Market for Diagnostic Tests for COVID-19

17.3.1 Global Market for COVID-19 Testing Kits by Technology

17.4 COVID-19 Addressable Personal Protection Equipment (PPE) Market

17.5 Estimated COVID-19 Addressable Critical Care Device Market

17.6 Global Market for “Other” COVID-19-Related Medical Supplies

17.6.1 Market Shares of Face Masks by Type of Material

17.6.2 Global Market Share for Hand Sanitizers by Type

17.7 Global COVID-19 Treatment Market

18. CELL THERAPY COMPANIES JOINING FORCES AGAINST COVID-19

18.1 Aspire Health Science

18.1.1 Filing of Investigational New Drug

18.1.2 ACT-20

18.2 Athersys, Inc.

18.2.1 MultiStem

18.2.2 MultiStem for COVID-19

18.2.3 MACOVIA Study

18.3 AlloVir

18.3.1 Technology

18.4 Bonus BioGroup, Ltd.

18.4.1 MesenCure

18.5 Caladrius Biosciences

18.5.1 CLBS12

18.5.2 CLBS14

18.5.3 CLBS16

18.5.4 CLBS119 for COVID-19

18.5.5 CLBS03

18.6 Capricor Therapeutics

18.6.1 CAP-1002

18.6.2 Exosomes

18.6.3 CAP-1002 for COVID-19

18.7 Celularity

18.7.1 IMPACT Platform

18.7.2 Collaboration with United Therapeutics

18.8 Celltex Therapeutics Corporation

18.8.1 FDA Approval Sought


____________________________________________

18.9 Citius Pharmaceuticals, Inc.

18.9.1 License Agreement with Novellus, Inc.

18.10 Cynata Therapeutics

18.10.1 Cynata and COVID-19

18.11 FibroGenesis

18.11.1 PneumoBlast

18.11.2 Patent for COVID-19 Induced ARDS

18.12 GC LabCell

18.13 Global Institute of Stem Cell Therapy and Research (GIOSTAR)

18.13.1 FDA Approval for COVID-19 Trial

18.14 Healios KK

18.14.1 New Treatment for ARDS

18.15 Hope Biosciences

18.15.1 Stem Cell Banking for Newborns

18.15.2 Stem Cell Banking for Adults

18.15.3 FDA Clearance for Phase II Trial of COVID-19

18.16 Kimera Labs, Inc.

18.16.1 Products

18.16.1.1 Exosomes: A Possible Therapy for COVID-19

18.17 Lattice Biologics, Ltd.

18.17.1 Products

18.17.2 Clinical Trial

18.18. Lineage Cell Therapeutics, Inc.

18.18.1 Cell Therapy Programs

18.18.1.1 OpRegen

18.18.1.2 OPC1

18.18.1.3 VAC2

18.18.1.4 COVID-19 Vaccine Development

18.19 Mesoblast, Ltd.

18.19.1 Remestemcel-L

18.19.2 Phase II/III Trial of Remestemcel-L

18.20 NantKwest, Inc.

18.20.1 NantKwest and ImmunityBio against COVID-19

18.21 Orbsen Therapeutics

18.21.1 Orbsen’s ORBCEL for COVID-19

18.22 Organicell

18.22.1 Organicell Flow

18.22.2 Organicell Flow for COVID-19

18.23 Pluristem Therapeutics, Inc.


____________________________________________

18.23.1 Pluristem’s Drug Development Alliance against COVID-19

18.24 Tianhe Stem Cell Biotechnologies, Inc.

18.25 The Cure Alliance

18.25.1 Cure Alliance’s Alliance with University of Miami against COVID-19

18.26 Vitro Biopharma

18.26.1 Cell Therapy for COVID-19

19. OTHER COMPANIES/INSTITUTIONS SPONSORING TRIALS FOR COVID-19

19.1 AlloVir and Baylor College of Medicine

19.2 Biostar Stem Cell Research Institute

19.3 CAR-T (Shanghai) Biotechnology, Co., Ltd

19.4 Orgenesis’ Cell-Based Vaccine

19.5 Peking University

19.6 REMSTEM’s Phase I/IIa for COVID-19

19.7 University of Miami-COVID-19 Research Programs

19.8 Wuhan Hamilton Biotechnology


____________________________________________

APPENDIX

Appendix 1: History of Pandemics

Appendix 1.1: A Timeline of Historical Pandemics

Appendix 1.2: Importing Disease

Appendix 1.3: Tracking Infectiousness

Appendix 1.4: Urbanization and Spread of Pandemics

Appendix 2: Global Pandemic Preparedness by Country

Appendix 3: The Math behind Social Distancing

Appendix 3.1: Effectiveness of Social Distancing

Appendix 4: Recent COVID-19 News in Brief

Appendix 4.1: Multiple Clinical Trials Test NO Gas for COVID-19

Appendix 4.2: U.S. Signed a Huge COVID-19 Drug Contract with Start-Up

Appendix 4.3: Cursory Glance at First COVID-19 Vaccine Data

Appendix 4.4: CEPI Grants $384 Million to Novavax’s COVID-19 Vaccine

Appendix 4.5: Adenoviral Vector Vaccines are the Front-Runners against COVID-19

Appendix 4.6: The Most Effective Masks for COVID-19

Appendix 4.7: FDA Approval for CRISPR-Based COVID-19 Diagnostic

Appendix 4.8: The Antiviral EIDD-2801 to Aim at COVID-19

Appendix 4.9: A Loose Alliance of Competitors against COVID-19

Appendix 4.10: About 69 Repurposed Drugs Can Block the Replication of COVID-19

Appendix 4.11: Lonza to make 1 Billion Doses of Gilead’s Remdesivir

Appendix 4.12: Merck KGaA to Ramp up Viral Vaccine Manufacturing

Appendix 4.13: DuPont, FeDEx and U.S. Government Teamed Up for PPE

Appendix 4.14: Fujifilm Tests Favipiravir against COVID-19

Appendix 4.15: Resolution to Produce I Million Swabs per Week

Appendix 4.16: BioNTech is in the Race for Vaccine


____________________________________________

List of Figures

Figure 2.1: Diagrammatic Cross Sectional View of COVID-19

Figure 2.2: Structure of the Spike Protein and Enzymes of COVID-19

Figure 2.3: COVID-19 Virus’s RdRp with nsp12 and nsp7

Figure 2.4: Schematic Representation of a Protease Dimer bound with two Inhibitors

Figure 2.5: The 3D Structure of the Spike Protein

Figure 2.6: The Antibody CR3022 Binding with the Spike Protein

Figure 2.7: Human Protein Complex Showing the Potential Binding Sites for the Virus

Figure 2.8: The Binding of Coronavirus to Target Protein on Human Cell

Figure 2.9: The Crystal Structure of the Enzyme ACE2

Figure 2.10: The Symptoms of COVID-19

Figure 2.11: CFR for COVID-19 in China over Time and Location

Figure 2.12: CFR for COVID-19 by Age

Figure 2.13: CFR for COVID-19 by Pre-Existing Health Issues

Figure 2.14: Case Fatality Rate for Select Countries and the World

Figure 3.1: The Steady Increase in Global Number of Confirmed Cases

Figure 3.2: Steep Increase in COVID-19 Deaths

Figure 3.3: Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020

Figure 3.4: Number of COVID-19 Deaths by Geography as of May 21, 2020

Figure 3.5: Number of COVID-19 Confirmed Cases in China, Jan-22 to May-21, 2020

Figure 3.6: COVID-19 Deaths in China

Figure 3.7: COVID-19 in the U.S.

Figure 3.8: COVID-19 Deaths in the U.S.

Figure 3.9: COVID-19 Confirmed Cases in U.K.

Figure 3.10: COVID-19 Deaths in U.K.

Figure 3.11: COVID-19 Confirmed Cases in Italy

Figure 3.12: COVID-19 Deaths in Italy

Figure 3.13: COVID-19 Confirmed Cases in France

Figure 3.14: COVID-19 Deaths in France

Figure 3.15: COVID-19 Confirmed Cases in Spain

Figure 3.16: Number of COVID-19 Confirmed Cases in Africa

Figure 3.17: Top Four Countries in COVID-19 Testing

Figure 4.1: WHO’s Estimated Fund to be raised in Response to COVID-19

Figure 5.1: Number of COVID-19-Related Scientific Papers

Figure 6.1: Distribution of Patents Related to SARS and MERS

Figure 6.2: Distributions of Biologics Patents Related to SARS and MERS

Figure 6.3: Distribution of Patents of Vaccines Related to SARS/MERS

Figure 7.1: Percent Share of Clinical Trials for COVID-19 by Region


____________________________________________

Figure 7.2: Number of Clinical Trials for COVID-19 by Study Type

Figure 7.3: Percent Shares of Interventional Types in COVID-19 Clinical Trials

Figure 7.4: COVID-19 Clinical Trials by Stage of Development

Figure 7.5: COVID-19 Clinical Studies by Funding Type

Figure 8.1: Clinical Trial Terminations/Withdrawals/Suspensions

Figure 8.2: Biotech IPOs by quarter

Figure 8.3: Market Cap Gain and Loss by Size Bracket between Q4 2019 and Q1 2020

Figure 8.4: Key COVID-19 Market Movers as of April 1, 2020

Figure 9.1: Percent Share of Emerging Treatments and Vaccines for COVID-19

Figure 10.1: Percent Share of Different Types of Vaccines in Development

Figure 10.2: Pattern of Revenue Generation by Flu Vaccine of GlaxoSmithKline

Figure 10.3: Historic Sales of H5N1 Vaccines

Figure 10.4: Historic Sales of H1N1 Influenza Vaccines

Figure 10.5: World’s Biggest Vaccine Makers and their Vaccine Sales

Figure 12.1: Sales of Roche’s Antiviral Tamiflu

Figure 12.2: Consensus Sales Forecast for Remdesivir

Figure 12.3: Structure of Remdesivir

Figure 12.4: Mechanism of Action of Remdesivir

Figure 16.1: EUAs Granted to COVID-19 Tests

Figure 16.2: EUA for Antigen Test and Home Test Kits

Figure 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027

Figure 17.2: Global Market for COVID-19 Drugs, 2020-2027

Figure 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027

Figure 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027

Figure 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027

Figure 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027

Figure 17.7: Global Market for Face Masks, 2020-2027

Figure 17.8: Market Shares of Face Masks by Type of Material

Figure 17.9: Global Market Share for Hand Sanitizers by Type

Figure 17.10: Global Market for COVID-19 Treatment, 2020-2027

Figure 18.1: Tianhe’s Stem Cell Educator Therapy

Figure App. 3.1: Social Distancing and Final Illness Attacking Rate


____________________________________________

List of Tables

Table 3.1: Total Confirmed Cases and Deaths from COVID-19

Table 3.2: Average Death per day due to Various Diseases

Table 3.3: Countries with Confirmed New Cases Decreasing/Increasing as of May

Table 3.4: Number of COVID-19 Confirmed Cases in Africa

Table 3.5: COVID-19 Tests Performed per 1,000 people by Select Country

Table 3.6: Top Four Countries in COVID-19 Testing

Table 4.1: Contributions to WHO for COVID-19 as of May 20, 2020

Table 4.2: CFE’s Allocations in 2020

Table 4.3: NIH Funding for COVID-19 Research as of May 27, 2020

Table 4.4: COVID-19 Research Fund through CARES Act in the U.S.

Table 5.1: Number of Published Papers by Category as of May 24, 2024

Table 5.2: Notable Journal Articles

Table 6.1: Key Proteins and their Roles in Viral Infection

Table 6.2: Patents and Potential Drug Candidates Related to Key Protein Targets

Table 6.3: Existing Drugs with Potential Applications for COVID-19

Table 6.4: Selected Patents Related to Small Molecule Drug Candidates

Table 6.5: Select Small Molecule Compounds in R&D to Treat COVID-19

Table 6.6: Small Molecules Identified by Structure Similarity and Therapeutic Usage

Table 6.7: Patents on Developing Therapeutic Antibodies against SARS

Table 6.8: Distribution of RNAi Patents related to SARS/MERS

Table 7.1: Number of Clinical Trials for COVID-19 by Country/Region

Table 7.2: Number of Clinical Trials for COVID-19 by Study Type

Table 7.3: Drugs used as Pharmacological Interventions in COVID-19 Trials

Table 7.4: COVID-19 Clinical Trials by Stage of Development

Table 7.5: COVID-19 Clinical Studies by Funding Type

Table 7.6: Commercial Projects in Clinical Trials for COVID-19

Table 7.7: Upcoming Readouts from Ongoing COVID-19 Clinical Trials

Table 8.1: The Ten Most Affected Biotechs Due to COVID-19 Crisis

Table 8.2: Clinical Trial Terminations/Withdrawals/Suspensions

Table 8.3: Valuable R&D Assets under Threat of Delay Due to COVID-19

Table 8.4: Commercially Sponsored Pivotal Trials due to Readout by the end of 2020

Table 8.5: Phase III Trials facing Shortages of Patients due to COVID-19

Table 8.6: The Biggest Phase III Trials that are still searching for Patients

Table 8.7: Threat to Trials of Near-Term Blockbusters

Table 8.8: COVID-19 Infected Orthopedic Companies

Table 8.9: COVID-19-Infected Cardiovascular Firms

Table 8.10: Select Pending Acquisitions in Healthcare

Table 8.11: Select COVID-19 Deals and Collaborations

Table 8.12: Key COVID-19 Market Movers as of April 1, 2020

Table 8.13: COVID-19-Related Stock Risers

Table 9.1: Current Count on Emerging Treatments and Vaccines for COVID-19

Table 10.1: Types of Vaccines in Development


____________________________________________

Table 10.1: Protein Sub-Unit Vaccines in Development against COVID-19

Table 10.2: RNA-Based Vaccines in Development for COVID-19

Table 10.3: Non-Replicating Viral Vector Vaccines in Development for COVID-19

Table 10.4: DNA Vaccines in Development for COVID-19

Table 10.5: Inactivated Virus Vaccines in Development for COVID-19

Table 10.6: Virus-like Particle Vaccines in Development for COVID-19

Table 10.7: Additional COVID-19 Vaccine Projects

Table 10.8: Cepi’s Call for Funding

Table 10.9: Estimated Cost of Select Pandemic Clinical Programs

Table 10.10: Most Recent Collaborations in Vaccine Sector

Table 10.11: Select COVID-19 Vaccines with Big Pharma Involvement

Table 11.1: Antibody Drugs in Development for COVID-19

Table 12.1: Antiviral Drugs in Development for COVID-19

Table 12.2: Estimated Cost of COVID-19 Clinical Program (Remdesivir)

Table 12.3: Comparison of Remdesivir’s Three Datasets

Table 12.4: Interim Data from Gilead’s Trial (NCT04292899)

Table 12.5: Additional COVID-19 Therapeutic Projects

Table 13.1: Repurposed Drugs in Development for COVID-19

Table 14.1: Cell-Based Therapies in Development for COVID-19

Table 15.1: Medical Devices in Development for COVID-19

Table 15.2: Select Makers of Modifiable Devices Eligible for EUAs

Table 15.3: Number of FDA-Approved Ventilators between 2014 and 2020

Table 16.1: Accuracy Figures for Select COVID-19 Antibody Tests

Table 16.2: Accuracy Figures for Top Eight COVID-19 Antibody Tests

Table 16.3: Top Ten COVID-19 Diagnostic Companies

Table 16.4: Commercially Available COVID-19 Diagnostic Tests

Table 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027

Table 17.2: Global Market for COVID-19 Drugs, 2020-2027

Table 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027

Table 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027

Table 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027

Table 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027

Table 17.7: Global Market for “Other” COVID-19-Related Medical Supplies, 2020-2027

Table 17.8: Global Market for COVID-19 Treatment, 2020-2027

Table App. 1.1: A Timeline of Historical Pandemics

Table App. 1.2: Ro Number of Pandemics

Table App. 2.1: Global Health Security Index Score


____________________________________________

About BioInformant:

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving market leaders that include Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data. Learn more at www.BioInformant.com.

BioInformant Worldwide, LLC

www.BioInformant.com

http://www.bioinformant.com/

covid-19 pipelines cell therapies, diagnostics, treatments and … › ... · 2 days ago ·...

Documents